ESMO Virtual Congress 2020 Prostate Cancer - Results from #40

Viewing 41-60 of 68 articles

ESMO Virtual Congress 2020: Neutrophil-Lymphocyte Ratio as a Prognostic and Predictive Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel vs. Abiraterone or Enzalutamide in the CARD Study

ESMO Virtual Congress 2020: 223Ra in Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer who Progressed to 1st line Abiraterone Acetate or Enzalutamide

ESMO Virtual Congress 2020: Exploring the Impact of Treatment Switching on the Interim Overall Survival Results of the PROfound Study

ESMO Virtual Congress 2020: Real-World Evidence For Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel: Comparison with the Randomized Clinical Study CARD

ESMO Virtual Congress 2020: Impact of Metastatic Lymph Node Burden on Survival in Patients with mHSPC from the "Docetaxel Comparison" of the STAMPEDE trial

ESMO Virtual Congress 2020: Clinical Benefit In Biomarker-Positive Patients with Locally Advanced or Metastatic Solid Tumors Treated with The PARP1/2 inhibitor Pamiparib in Combination with Low-Dose Temozolomide

ESMO Virtual Congress 2020: Invited Discussant: Refining Therapy Development in Prostate Cancer

ESMO Virtual Congress 2020: TALAPRO-1: Talazoparib Monotherapy in Men with DNA Damage Response Alterations and Metastatic Castration-Resistant Prostate Cancer: Exploration of DDRalt Germline/Somatic Origin

ESMO Virtual Congress 2020: 617MO (MANSMED) & 618MO Local Therapy to the Primary Tumor For Newly Diagnosed, Oligo-Metastatic Prostate Cancer

ESMO Virtual Congress 2020: Local Therapy to the Primary Tumor for Newly Diagnosed, Oligo-Metastatic Prostate Cancer: A Prospective Randomized, Phase 2, Open-Label Trial

ESMO Virtual Congress 2020: Repurposing Metformin as Anticancer Drug: Preliminary Results of Randomized Controlled Trial in Advanced Prostate Cancer (MANSMED)

ESMO Virtual Congress 2020: Efficacy of BN-Brachyury (BNVax) + Bintrafusp Alfa (BA) + N-803 in Castration-Resistant Prostate Cancer: Results From a Preliminary Analysis of the Quick Efficacy Seeking Trial (QuEST1)

ESMO Virtual Congress 2020: Cabazitaxel Activity in Men with Metastatic Castration Resistant Prostate Cancer with and without DNA Damage Repair Defects

ESMO Virtual Congress 2020: Clinical Impact of Somatic Alterations in Prostate Cancer Patients with and Without Previously Known Germline BRCA1/2 Mutations: Results from PROREPAIR-A Study

ESMO Virtual Congress 2020: Invited Discussant 615MO VERU-111 Phase 1b/2 Study & 616MO Results from a Preliminary Analysis of the Quick Efficacy Seeking Trial (QuEST1)

ESMO Virtual Congress 2020: Phase 1b/2 Study of VERU-111, Novel, Oral Tubulin Inhibitor, in Men with Metastatic Castration-Resistant Prostate Cancer Who Failed an Androgen Blocking Agent

ESMO Virtual Congress 2020: Imaging Based Prostate Cancer Screening Among BRCA Mutation Carriers – Results from the First Round of Screening

ESMO Virtual Congress 2020: Pembrolizumab Plus Docetaxel and Prednisone in Patients with Abiraterone Acetate– or Enzalutamide– Pretreated mCRPC: KEYNOTE-365 Cohort B Update

ESMO Virtual Congress 2020: Pembrolizumab Plus Olaparib in Patients With Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-365 Cohort A Update

ESMO Virtual Congress 2020: KEYNOTE-199 Phase 2 Study of Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant mCRPC: Cohorts 4 and 5 Update

1
2
3
4